CD163 and melanoma: Notably, TAM-related chemokines, such as CXCL5, CXCL10, and CCL22, as well as a TAM-activation marker, soluble (s)CD163, could be predictive markers for efficacy and immune-related adverse events (irAEs) in anti-PD1 Abs-treated advanced melanoma patients (15–17).